This inventor holds 1 USPTO granted patent. Top assignee: Corixa Corporation. Active years: 2003.
Company Filing History:
Years Active: 2003
Title: Mark Brannon: Innovator in Leishmaniasis Therapy
Introduction
Mark Brannon is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of medical research, particularly in the area of leishmaniasis, a disease caused by parasites of the Leishmania genus. His innovative work has led to the development of therapeutic and diagnostic methods that aim to combat this challenging disease.
Latest Patents
Mark Brannon holds 1 patent related to his research. His patent, titled "Leishmania antigens for use in the therapy and diagnosis of leishmaniasis," discloses compositions and methods for preventing, treating, and detecting leishmaniasis. The patent includes polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or variants thereof. Additionally, it provides vaccines and pharmaceutical compositions that may be used for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.
Career Highlights
Mark Brannon is associated with Corixa Corporation, where he has been able to apply his expertise in immunology and infectious diseases. His work at Corixa has allowed him to focus on developing innovative solutions to address significant health challenges.
Collaborations
Throughout his career, Mark has collaborated with several talented individuals, including Yasir A W Skeiky and Davin C Dillon. These collaborations have contributed to the advancement of research in the field of leishmaniasis and have fostered a productive environment for innovation.
Conclusion
Mark Brannon's contributions to the field of leishmaniasis therapy highlight the importance of innovation in medical research. His patent and work at Corixa Corporation demonstrate his commitment to improving health outcomes for patients affected by this disease.